General Considerations for the Clinical Evaluation of Drugs in Infants and Children

General Considerations for the Clinical Evaluation of Drugs in Infants and Children
Author :
Publisher :
Total Pages : 28
Release :
ISBN-13 : UOM:39015003205070
ISBN-10 :
Rating : 4/5 ( Downloads)

Book Synopsis General Considerations for the Clinical Evaluation of Drugs in Infants and Children by : United States. Food and Drug Administration. Bureau of Drugs

Download or read book General Considerations for the Clinical Evaluation of Drugs in Infants and Children written by United States. Food and Drug Administration. Bureau of Drugs and published by . This book was released on 1977 with total page 28 pages. Available in PDF, EPUB and Kindle. Book excerpt:


General Considerations for the Clinical Evaluation of Drugs in Infants and Children Related Books

General Considerations for the Clinical Evaluation of Drugs in Infants and Children
Language: en
Pages: 28
Authors: United States. Food and Drug Administration. Bureau of Drugs
Categories: Drugs
Type: BOOK - Published: 1977 - Publisher:

DOWNLOAD EBOOK

General Considerations for the Clinical Evaluation of Drugs in Infants and Children
Language: en
Pages: 28
Authors: United States. Food and Drug Administration
Categories: Chemotherapy
Type: BOOK - Published: 1977 - Publisher:

DOWNLOAD EBOOK

General considerations for the clinical evaluation of drugs
Language: en
Pages: 20
Authors: United States. Food and Drug Administration. Bureau of Drugs
Categories: Drugs
Type: BOOK - Published: 1977 - Publisher:

DOWNLOAD EBOOK

General Considerations for the Clinical Evaluation of Drugs
Language: en
Pages: 20
Authors: United States. Food and Drug Administration
Categories: Drugs
Type: BOOK - Published: 1977 - Publisher:

DOWNLOAD EBOOK

Safe and Effective Medicines for Children
Language: en
Pages: 432
Authors: Institute of Medicine
Categories: Medical
Type: BOOK - Published: 2012-10-13 - Publisher: National Academies Press

DOWNLOAD EBOOK

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used fo